Bovine blood contract
Forecast New Requirement Updated
- Agency
-
Food and Drug Administration
Department of Health and Human Services
- Solicitation expected
- Not on record
- Estimated value
- $10,000 to $25,000
- Set-aside
- No set-aside
Forecast facts
- Anticipated award
- NAICS code
- Not on record
- Points of contact
-
- CDRH Acquisition Liaison cdhracquisitions@fda.hhs.gov
Forecast details come from HHS's procurement forecast. Agencies' dates and values are estimates.
About this forecast
The Food and Drug Administration is awarding a contract for defibrinated bovine blood to support pulse oximetry wearable device research, with an estimated award date of July 1, 2027. The blood will be used for phantom-based blood flow testing to validate blood flow setup and assess how biological confounders such as blood oxygen saturation and perfusion affect sensor accuracy. The contract is intended to ensure timely and reliable delivery, reducing delays from one-off purchases and supporting uninterrupted research.
The estimated award value ranges from $10,000 to $25,000. No set-aside applies to this procurement. Inquiries should be directed to cdhracquisitions@fda.hhs.gov.
Forecast text
BPID: 886 - Defibrinated bovine blood contract with Lampire Biological Laboratories for phantom-based blood flow testing in support of pulse oximetry wearable device research. This material is needed to validate our blood flow setup and study how changes in biological confounders such as blood oxygen saturation and perfusion affect sensor accuracy. A contract with Lampire will ensure timely and reliable delivery of defibrinated bovine blood, reducing delays associated with one-off purchases and supporting uninterrupted research.
On GovTribe
Work this forecast
- Track it in your pipeline
- Find teaming partners
- Similar forecasts
- Ask GovTribe AI about this forecast